期刊文献+

结肠癌组织标本Rho解离抑制因子2的表达及其与临床病理的关系 被引量:2

Expression of Rho dissociation inhibitor 2 in colon cancer tissues and its correlation with clinico-pathological features
原文传递
导出
摘要 目的探讨结肠癌Rho解离抑制因子2(RhoGDl2)基因的表达及其与临床病理的关系。方法运用组织芯片技术、免疫组织化学法检测75例结肠癌患者原发癌灶和癌旁正常结肠组织的RhoGDl2的表达及其与相应结肠癌临床病理参数之间的关系。运用Westernblot和实时定量聚合酶链反应(Real-timePCR)检测18例配对结肠腺癌原发灶组织和癌旁5cm正常结肠组织的RhoGDl2的表达。结果RhoGDl2阳性率在结肠癌原发癌灶和癌旁正常组织分别为73.33%和33.33%(P〈0.05);RhoGDl2阳性率与临床TNM分期相关(P〈0.01),与原发灶T分期范围相关(P〈0.05),与淋巴结N分期、远处转移M无明显相关(P〉0.05)。18例结肠癌RhoGDl2Westernblot灰度值高于正常组织的4.8倍(P〈0.05)。Real-timePCR结果显示癌灶组RhoGDl2相对表达量高于癌旁对照组(P〈0.05);RhoGDl2表达阳性率与临床TNM分期明显相关(P〈0.01),与原发灶T分期明显相关(P〈0.05)。结论RhoGDl2在结肠癌中表达上调,与临床TNM分期明显相关。 Objective To investigate the Rho dissociation inhibitor 2 (RhoGDI2) gene expression in colon cancer tissues and its correlation with clinicopathological features. Methods Tissue microarray and immunohistochemistry were used to detcet the expression of RhoGDI2 in the primary lesions and adja- cent colon tissues of 75 cases of colon cancer, and its correlation with clinicopathological features of colon cancer was analyzed. Western blotting and real-time polymerase chain reaction (Real-time PCR) were used to examine the RhoGDI2 expression in the primary lesions and adjacent colon tissues of 18 cases of co- lon adenocarcinoma. Results The positive RhoGDI2 expression rate in primary lesions and adjacent nor- mal tissues of colon cancer was 73.33% and 33.33% respectively (P 〈 0. 05). The positive expression rate of RhoGDI2 was correlated with TNM staging significantly ( P 〈 0. 05 ) and primary tumor T lymph node N stage related to the scope (P 〈 0. 05), but not with distant metastasis M and lymph node N stage (P〉0. 05). The gray values of RhoGDI2 in 18 cases of colon adenocarcinoma tissues were 4. 8 times higher than normal tissues ( P 〈 0. 05 ). Real-time PCR results revealed that the relative expression of RhoGDI2 in the primary lesions was higher than in control group (P 〈 0. 05). Conclusion Up-regulation of RhoGDI2 expression in colon cancer is significantly correlated with TNM staging. RhoGDI2 may be one of the colon cancer prognosis factors and the potential therapeutic targets.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2012年第11期2297-2299,共3页 Chinese Journal of Experimental Surgery
基金 广东省自然科学基金自由申请项目(101510089-01000071)
关键词 结肠癌 组织芯片 Rho解离抑制因子2 Colon carcinoma Tissue microarray Rho dissociation inhibitor 2
  • 相关文献

参考文献10

  • 1Bishop AL,Hall A. Rho GTPases and their effector proteins. Biochem J, 2000,348 : 241 -255.
  • 2Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer, 2002,2 : 133-142.
  • 3Jaffer AB, Hall A. Rho GTPases in transformation and metastasis. Adv Cancer Res ,2002,84:57-80.
  • 4Zhang Y, Zhang B. IM-GDI : a Rho GTPase regulator, promotes breast cancer eell invasiveness. Cancer Res,2006,66:5592-5598.
  • 5Cho HJ, Beak KE, Park SM. RhoGDI2 expression is associated with tumor grouth and malignant progression of gastric cancer. Clin Cacer Res,2009,15:2612-2619.
  • 6Harding MA,Theodorescu D. RhoGDI2 A new metastasis suppressor gene Discovery and clinical translation. Urol 0ncol,2007,25:401- 406.
  • 7Gildea JJ,Seraj MJ,Oxford G. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res,2002,62:6418-6423.
  • 8Tian T,Hao J,Xu AJ. Determination of metastasis-associated proteins tbr non-small cell lung cancer by comparative proteomic analysis. Cancer Sci,2007,98 : 1265-1274.
  • 9Zhao L, Wang H, Li J, et al. Over expression of Rho GDP-dissoeia- tion inhibitor alpha is associated with tumor progression and poor prognosis of colorectal cancer. J Promeome Res ,2008,7:39944003.
  • 10Dovas A, Couchman JR. RhoGDI:muhiple functions in the regulation of Rho family GTPase activities. Biochem J ,2005,390:1-9.

同被引文献6

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部